$AUTL News
Last published 1d ago
- 1d agoAUTLAutolus Therapeutics Presents Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026GlobeNewswireAutolus announced data from the ongoing CARLYSLE trial, a Phase 1 clinical trial of obe-cel in severe refractory systemic lupus erythematosus.
- 1d agoAUTLAutolus Therapeutics plc - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 9.01
- 1d agoAUTLAutolus Therapeutics Reports Third Quarter 2026 Financial Results and Business UpdatesGlobeNewswireAutolus reports third quarter 2026 financial results, including AUCATZYL net product revenue and guidance, and pipeline updates.
- 2d agoAUTLAutolus Therapeutics to Participate in the Jefferies Global Healthcare ConferenceGlobeNewswireLONDON and GAITHERSBURG, Md., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed
- 2d agoAUTLAutolus Therapeutics to Participate in the Jefferies Global Healthcare ConferenceGlobeNewswireAutolus will present at the Jefferies Global Healthcare Conference on November 17, 2026 in London.
- 1w agoAUTLAutolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2026GlobeNewswireLONDON and GAITHERSBURG, Md., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed
- 1w agoAUTLAutolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireLONDON and GAITHERSBURG, Md., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed
- 2w agoAUTLAutolus Therapeutics to Report Third Quarter 2026 Financial Results and Host Conference Call on November 10, 2026GlobeNewswireLONDON and GAITHERSBURG, Md., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed
- 2mo agoAUTLAutolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus NephritisGlobeNewswireLONDON and GAITHERSBURG, Md., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed
- 3mo agoAUTLAutolus Therapeutics Reports Second Quarter 2026 Financial Results and Business UpdatesGlobeNewswireCompany reports AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $45.7 million in Q2 2026, an increase of 119% year-over-yearFY 2026 net product revenue guidance increased to $140 - $150 millionGross
- 3mo agoAUTLAutolus Therapeutics to Report Second Quarter 2026 Financial Results and Host Conference Call on August 11, 2026GlobeNewswireLONDON and GAITHERSBURG, Md., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed
- 3mo agoAUTLAutolus Therapeutics Reports Preliminary Second Quarter 2026 Net Product Revenue and Announces Credit Facility of up to $250 Million with Perceptive AdvisorsGlobeNewswireCompany reports preliminary Q2 2026 AUCATZYL net product revenue of approximately $45 million and gross margin of approximately 35% year-to-date FY 2026 sales guidance increased to $140 – $150 million, from $120 – $135
- 4mo agoAUTLAutolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireLONDON & GAITHERSBURG, Md., July 01, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation
- 4mo agoAUTLAutolus Therapeutics to Participate in Upcoming Investor ConferenceGlobeNewswireLONDON and GAITHERSBURG, Md., June 25, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed
- 5mo agoAUTLAutolus Therapeutics Receives Prix Galien UK AwardGlobeNewswireLONDON and GAITHERSBURG, Md., June 12, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T
- 5mo agoAUTLAutolus Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireLONDON and GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T
- 5mo agoAUTLAutolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026GlobeNewswireLONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T
- 6mo agoAUTLAutolus Therapeutics Reports First Quarter 2026 Financial Results and Business UpdatesGlobeNewswireAUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $26.2 million for the first quarter of 2026, reflecting strong launches in the US and most recently the UKCompany achieves positive gross margin
- 6mo agoAUTLAutolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026GlobeNewswireLONDON and GAITHERSBURG, Md., May 05, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T
- 6mo agoAUTLAutolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost ReductionGlobeNewswireInitiative focused on driving gross profit margin and path to profitability for the ALL businessCompany will reduce headcount by approximately 13% while doubling manufacturing of products for commercial and clinical
- 6mo agoAUTLAutolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireLONDON and GAITHERSBURG, Md., April 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed
- 7mo agoAUTLAutolus Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireLONDON and GAITHERSBURG, Md., April 07, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed
- 7mo agoAUTLAutolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business UpdatesGlobeNewswireAUCATZYL® (obecabtagene autoleucel) net product revenue of $23.3 million* for the fourth quarter of 2025 and $74.3 million* for the full year of 2025AUCATZYL® UK launch underway following successful
- 8mo agoAUTLAutolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026GlobeNewswireLONDON and GAITHERSBURG, Md., March 16, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed
- 8mo agoAUTLAutolus Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireLONDON and GAITHERSBURG, Md., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T
- 9mo agoAUTLIMNMMRNAONCY+1The $71 Billion Cancer Shift: Why The FDA Is Speeding UpGlobeNewswireVANCOUVER, British Columbia, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The market is waking up to a $71 billion reality[1]. We are seeing a decisive move away from broad chemotherapy and
- 9mo agoAUTLAutolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireLONDON and GAITHERSBURG, Md., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T
- 10mo agoAUTLAutolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026GlobeNewswireCompany expects preliminary unaudited AUCATZYL® net product revenue of approximately $24 million for the fourth quarter of 2025 and approximately $75 million for the full year of 2025Autolus anticipates full year
- 10mo agoAUTLAutolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell ShuttleTM PlatformBusiness WireAutolus will evaluate Cellares' fully automated, high-throughput manufacturing platform in preparation for expansion into new indications Autolus Therapeutics plc (NASDAQ:AUTL), a commercial-stage biopharmaceutical
- 10mo agoGTBPREGNGMABAUTL+1Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030PR NewswireUSA News Group News Commentary – The recent FDA approval in November of the first bispecific antibody combination for second-line blood cancer...
- 11mo agoAUTLAutolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025GlobeNewswireData show deep, durable responses in the 50 million cell dose level cohort; initial data suggest substantial early improvement in three patients dosed with 100 million cellsAll patients show deep B-cell depletion after
- 11mo agoAUTLAutolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025GlobeNewswireObe-cel demonstrates high remission rates in pediatric patients with high-risk r/r B-ALL with overall response rate (ORR) of 95.5%; low rates of high-grade cytokine release syndrome (CRS) and immune effector
- 11mo agoAUTLAutolus Therapeutics Appoints Ryan Richardson to Board of DirectorsGlobeNewswireLONDON and GAITHERSBURG, Md., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation
- 11mo agoAUTLNICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹GlobeNewswireLONDON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell
- 12mo agoAUTLAutolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in LondonGlobeNewswireLONDON and GAITHERSBURG, Md., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation
- 12mo agoAUTLAutolus Therapeutics Reports Third Quarter 2025 Financial Results and Business UpdatesGlobeNewswireCompany reports Q3 2025 AUCATZYL® net product revenue of $21.1 million and deferred revenue of $7.6 million; 60 authorized treatment centers achieved ahead of targetClinical execution and data generation to support
- 1y agoAUTLAutolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025GlobeNewswireLONDON and GAITHERSBURG, Md., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation
- 1y agoAUTLAutolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025GlobeNewswireLONDON & GAITHERSBURG, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation
- 1y agoAUTLAutolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025GlobeNewswireData from the Phase 1 CARLYSLE study in severe refractory systemic lupus erythematosus (srSLE) suggests obe-cel is well tolerated with no ICANS or high-grade CRS; 50 million cell dose selected for Phase 2 pivotal
- 1y agoAUTLAutolus Therapeutics Announces First Patient Dosed in Phase 1 Trial of Obecabtagene Autoleucel (Obe-Cel) in Patients with Progressive Multiple SclerosisGlobeNewswireLONDON and Gaithersburg, Md., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation
- 1y agoAUTLAutolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireLONDON and GAITHERSBURG, Md., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation
- 1y agoAUTLAutolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025GlobeNewswireLONDON and GAITHERSBURG, Md., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation
- 1y agoAUTLAutolus Therapeutics plc (AUTL) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoAUTLAutolus Therapeutics Reports Second Quarter 2025 Financial Results and Business UpdatesGlobeNewswireCompany reports Q2 2025 AUCATZYL® net product revenue of $20.9 million and $29.9 for the first six months of 2025Company recently received conditional marketing authorization from U.K. Medicines and Healthcare
- 1y agoAUTLAutolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025GlobeNewswireLONDON and GAITHERSBURG, Md., July 24, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation
- 1y agoAUTLAutolus Therapeutics' CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)GlobeNewswireApproval is based on FELIX clinical trial of obecabtagene autoleucel (obe-cel) in adult patients with r/r B-ALL, demonstrating high and durable response rates and low toxicityEC approval follows positive CHMP opinion,
- 1y agoAUTLAutolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireLONDON & GAITHERSBURG, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation
- 1y agoONCYINDPCATXSLS+1Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug PricesPR NewswireEquity Insider News Commentary – Rising rates of cancer are going to come at a major cost, and it's looking more and more like the solution is going...
- 1y agoAUTLAutolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) CongressGlobeNewswireMedian duration of response in FELIX study now 42.6 months after an additional 11 months of follow upMore than half of patients still in remission at 24 months38% of ongoing responders did not receive any subsequent
- 1y agoAUTLAutolus Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireLONDON, May 29, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies,